Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

solidated Statements of Operations:Three months endedTwelve months ended(in thousands, except per share data)

December 31,December 31,2010200920102009(unaudited)Revenue:Net product sales

$ 121,623$ 87,835$ 439,012$ 310,449Costs and Expenses:Cost of sales (excluding amortization of product rights)

17,93411,94861,28840,214Research and development

10,4608,92539,61352,083Selling, general and administrative

24,33421,17495,66489,316Intangible amortization

7,0846,75129,35728,183Goodwill impairment

---65,099Impairment loss

-3,424-3,424Other operating expenses

858-1,390-Total costs and expenses

60,67052,222227,312278,319Operating income

60,95335,613211,70032,130Interest income

14037372352Interest expense

(2,960)(2,805)(11,616)(11,609)Other (loss) income, net

(905)-430-Gain on long-term debt repurchase

---9,079Income before income tax expense

57,22832,845200,88629,952Income tax expense

19,76220,83175,27841,029Net income (loss)

$   37,466$ 12,014$ 125,608$ (11,077)Basic net income (loss) per share

$
.48$
.16$
.61$
(0.14)Diluted net income (loss) per share

$
.43$
.15$
.47$
(0.14)Shares used in computing net income (loss) per shareBasic

78,04977,44277,82077,423Diluted

90,93478,39490,08177,423VIROPHARMA INCORPORATEDSelected Financial InformationReconciliation of GAAP Net Income (loss) to Adjusted Net IncomeAn itemized reconciliation between net income (loss) and adjusted net income on a non-GAAP basis is as follows:(in thousands)

Three months endedTwelve months endedDecember 31,December 31,2010200920102009(unaudited)(unaudited)GAAP net  income (loss)

$ 37,466$ 12,014$ 125,608$ (11,077)Adjustments:Non-cash interest expense

1,9441,8047,5177,291Intangible amortization

7,0846,75129,35728,183Step-up of inventory

112-8966,913Stock compensation

2,8172,43811,1
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  Rahal Letterman Lanigan ... human cord blood stem cell banking and therapeutics, announced ... the No. 16 Acorn Stairlifts Indy car driven by ... the remainder of the IZOD IndyCar 2013 season.   ... will work to support awareness of umbilical cord blood ...
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... May 23, 2013 BioTrends Research Group, ... firms for specialized biopharmaceutical issues, finds that, unaided, ... disease specialists reported that in the past six ... delaying treatment) in anticipation of the next generation ... ago, when only 6 percent reported that they ...
(Date:5/23/2013)... 23, 2013 Northwest Biotherapeutics (NASDAQ: ... ® personalized immune therapies for solid tumor cancers, ... this year,s American Society Of Clinical Oncology (ASCO) meeting ... leadership role in immune therapy.  (Logo: ... is the pre-eminent conference focused on clinical treatment of ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3
... a single venture capital deal from January through March this ... ,Venture capitalists in the state said that the lack of ... state, though it is another reminder that capital is hard ... investments have come erratically, sometimes adding up to around $20 ...
... part of Emergis Inc. for about $13.8 million in ... mortgage lending industry. , ,Emergis is headquartered in Montreal, ... exchanges. Fiserv plans to acquire its eLending U.S. operation, ... based in McLean, Virginia, and Fiserv expects Emergis' employees ...
... the IT industry is gripped in a mania for centralization right ... black, but since it's technology, I'll have to settle for saying ... some serious competition as the option of first resort when it ... might not fly in the states of Kansas or Ohio, this ...
Cached Biology Technology:Money Tree survey shows lull in Wisconsin venture capital deals 2Money Tree survey shows lull in Wisconsin venture capital deals 3Centralization mania takes over 2Centralization mania takes over 3Centralization mania takes over 4
(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than ... of intellectual property at PNNL,s annual Intellectual Property ... The Department of Energy national laboratory named materials ... his work developing battery materials that can store ... electrical grid, and reduce the time it takes ...
(Date:5/23/2013)... at Rollins School of Public Health at Emory ... of Technology, have received a $4 million grant ... at Emory University (Health and Exposome Research Center: ... exposome-based center grant awarded in the United States. ... the National Institute of Environmental Health Sciences (NIEHS) ...
(Date:5/23/2013)... tight wrapping of genomic DNA around nucleosomes in ... expression. A team of Ludwig-Maximilians-Universitaet (LMU) in Munich ... to be locally displaced from nucleosomes for transcription. ... stored in the cell nucleus, wrapped around disk-shaped ... of four different histone proteins and accommodating two ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Biochemistry: Unspooling DNA from nucleosomal disks 2
... the first time, researchers at the University of Alberta in ... a description to an ancient mammal that still defies classification. ... provide the first and only comprehensive account of the creature, ... of the teeth. Horolodectes lived about 60 million years ago, ...
... attack, meant immediate death for the primitive human. Modern ... a car crash, gunshot or fall thanks to high-tech emergency ... when it survives an injury that would have been fatal ... time, mechanisms in place to protect people from disease misfire ...
... new work, researchers report that the ability of plants to ... can be overcome by some insects, and that such adaptation ... parasites may in turn evolve to deal with high levels ... of Colorado State University and colleagues there and at the ...
Cached Biology News:Researchers give name to ancient mystery creature 2PNAS study reveals why organs fail following massive trauma 2PNAS study reveals why organs fail following massive trauma 3PNAS study reveals why organs fail following massive trauma 4PNAS study reveals why organs fail following massive trauma 5New moth variety disarms plants guarded by selenium 2
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
WTAP Antibody...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Biology Products: